On 17th June 2016, GetReal held the conference “Putting Real World Healthcare Data to Work” in London. The aim of the conference was to gather perspectives of key stakeholders on the potential value of GetReal in decision-making within industry, regulatory authorities, HTAs, and for patients. Following a series of [...]
Duane Schulthess of Vital Transformation sits down for a one on one discussion with Luca Pani, the Director General of the Italian Medicines Agency, to discuss his new book "Sustainable Innovation: Medicines and the Challenges for the Future of our National Health Service". This 30 minute podcast recording [...]
On 10 May 2016, thought leaders involved in the IMI GetReal initiative met in Bern, Switzerland for the webinar “Synthesis and integration of real-world evidence in network meta-analyses and outcome prediction”. The webinar gave participants an understanding of important methodological key deliverables achieved by the IMI GetReal team. [...]
On 18 April 2016, leaders from IMI GetReal met at the Takeda offices in London for a live broadcast: “Introduction to the concept of drivers of effectiveness”. The broadcast introduced the concept of drivers of effectiveness and provided an overview of the methods that can be used to identify them [...]
March 23, 2016
On 23 March 2016, leaders from the IMI GetReal project met in London to for the webinar “Effectiveness research: navigating real world solutions”. Part of the IMI GetReal project has focused on exploring how best to tackle effectiveness research before marketing authorisation. Towards this end, the project has gathered valuable insight from stakeholders and decision-makers on the value of real-world evidence and the acceptability of approaches to gather that evidence to support marketing authorisation and subsequent HTA assessment.
March 9, 2016
It's not really about the technology - it's about the political will. We know how to solve the data problems... the problem is how we get the right people to buy in...The future challenge is not going to be technology, it's going to be will and money - I think Europe can do it and I think COCIR can help.
March 8, 2016
In contrast, EMIF has brought together a group of people that enabled identification of the right cohorts through the cohort selection tool, or the EMIF catalogue. In a study that we’re doing at the moment we’ve already completed a study of 500 individuals and we’re now embarking on a study of 1000 individuals.
March 8, 2016 If you can gather all this data together – from historical data i.e. disease history, to the ‘omics’ data and genetic data – we could, for instance, develop a web-based service where patients could see how their past and current lifestyle decisions affect their disease risks. For example, if a patient knows he has a higher risk for smoking-induced cancer, that might motivate him to stop smoking – or if he has a genetic tendency to become obese in later life, then maybe that will motivate him to follow a healthier lifestyle.
March 8, 2016 Patient data, at the end of the day, belongs to individual people. We are sensitive to that and I think having the input of an independent external ethical advisory board shows just how careful we are being, which is important for the public to know. Having convened that group and meeting with them regularly is a very big step forward.
February 7, 2016
When asked about the issues around harnessing health data in Europe in Washington DC on October 27th, Prof Hans Georg Eichler, Senior Medical Officer of the European Medicines Agency responded, "I come from an area with hysterical data protection.”[1] Why would a regulator feel this way? Surely, Europe’s public health systems have access to health data that is second to none?